Immune System

Hypogammaglobulinemia: workup and replacement

Clinical Overview and When to Suspect Hypogammaglobulinemia

— Primary immunodeficiency (PID): Common variable immunodeficiency (CVID) is the most common symptomatic adult PID; others include X-linked agammaglobulinemia (XLA, infant boys), selective IgA deficiency, hyper-IgM syndromes, specific antibody deficiency.

— Secondary (far more common in adults): drug-induced (rituximab, anti-CD20s, chronic corticosteroids, anti-epileptics like phenytoin/carbamazepine, mycophenolate), protein loss (nephrotic syndrome, protein-losing enteropathy), hematologic malignancy (CLL, multiple myeloma, lymphoma), post-HSCT, thymoma (Good syndrome).

— ≥2 pneumonias in a year, or ≥4 sinusitis/otitis episodes/year in an adult

— Recurrent encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis)

— Bronchiectasis without obvious cause (CF, ciliary disease)

— Chronic Giardia or norovirus diarrhea, especially with sinopulmonary infections

— Autoimmune cytopenias + recurrent infection (classic CVID picture: ITP/AIHA)

— Granulomatous-lymphocytic interstitial lung disease (GLILD)

— Patient on rituximab who develops recurrent infections after therapy

Board pearl: Any adult with recurrent encapsulated-organism sinopulmonary infections plus low IgG should be worked up for CVID — but always rule out multiple myeloma and rituximab exposure first, as these are the most common secondary causes tested.

Definition: Reduced serum immunoglobulins (IgG, often with IgA and/or IgM) leading to impaired humoral immunity and recurrent sinopulmonary or encapsulated-organism infections.

Primary vs secondary — the central Step 3 fork:

When to suspect on Step 3:

Epidemiology: CVID prevalence ~1:25,000; bimodal age of onset (childhood and 20s–40s); diagnostic delay averages 6–8 years — a recurring board theme.

Why it matters in ambulatory practice: early IgG replacement reduces serious infections, hospitalizations, and bronchiectasis progression; under-recognition is a major patient-safety gap.

Presentation Patterns and Key History

— Sinopulmonary: recurrent sinusitis, otitis media, bronchitis, pneumonia — encapsulated organisms (pneumococcus, H. flu, Moraxella)

— GI: chronic/recurrent Giardia, Campylobacter, Salmonella, norovirus; nodular lymphoid hyperplasia

— Skin/soft tissue: less prominent unless neutropenia coexists

— Enteroviral meningoencephalitis — classic in XLA but also seen in CVID

— Autoimmunity: ITP, autoimmune hemolytic anemia, pernicious anemia, thyroiditis, vitiligo

— Granulomatous disease: sarcoid-like granulomas in lung, liver, spleen, lymph nodes

— GLILD: dyspnea, restrictive PFTs, ground-glass on CT

— Malignancy: ~5× lifetime risk of NHL, gastric cancer (screen for H. pylori)

— Splenomegaly and lymphadenopathy — often mistaken for lymphoma

— Frequency, severity, and organisms of infections; antibiotic courses per year

— Drug history: rituximab, obinutuzumab, chronic steroids, anti-epileptics, MMF — secondary hypogammaglobulinemia

— Family history: consanguinity, infant deaths, known PID — XLA, hyper-IgM

— Vaccine response history (live vaccine complications suggest combined deficiency)

— Diarrhea, weight loss, edema (consider PLE/nephrotic)

— Hematologic symptoms suggesting CLL/myeloma (bone pain, fatigue, bleeding)

— Bronchiectasis in a non-smoker without CF

— Need for IV antibiotics for "routine" infections

— Failure to thrive in pediatric patient with recurrent infections after 6 months (maternal IgG wanes)

Key distinction: XLA presents at 6–12 months with absent B cells and absent tonsils/lymph nodes in a male infant; CVID presents later (often adulthood), normal-to-low B cells, and prominent autoimmunity/granulomas — exam favorite.

Infectious phenotype (dominant feature):

Non-infectious CVID features (~25–30% of patients):

High-yield history elements:

Red flags prompting immediate workup:

Physical Exam Findings

— May appear well between infections; chronic disease appearance if bronchiectasis/malabsorption advanced

— Weight loss, cachexia → consider PLE, malignancy, chronic Giardia

— Scarred tympanic membranes from recurrent otitis

— Chronic rhinosinusitis: mucopurulent discharge, nasal polyps, sinus tenderness

— Absent tonsils and palpable lymph nodes — XLA hallmark

— Conversely, diffuse lymphadenopathy and tonsillar prominence in CVID

— Crackles, wheezing, clubbing → bronchiectasis

— Decreased breath sounds, dullness → consolidation or effusion

— Velcro crackles → GLILD or fibrosis

— Usually normal; sepsis from breakthrough infection may present with tachycardia, hypotension, narrow pulse pressure

— Right heart strain (loud P2, RV heave) in advanced bronchiectasis with cor pulmonale

— Splenomegaly (common in CVID, ~30%)

— Hepatomegaly with nodular regenerative hyperplasia

— Diffuse tenderness if chronic enteritis

— Vitiligo, alopecia (autoimmunity)

— Granulomas resembling sarcoid

— Petechiae (ITP) or pallor (AIHA)

— Septic arthritis (especially mycoplasma/ureaplasma — classic in hypogammaglobulinemia)

— Polyarthritis from immune dysregulation

— Subtle cognitive changes or focal deficits → consider chronic enteroviral meningoencephalitis (subacute, devastating)

Step 3 management: When you find splenomegaly + cytopenias + recurrent infections, don't anchor on lymphoma — send quantitative immunoglobulins early. CVID with autoimmune cytopenia is a frequent missed diagnosis on the wards and a high-yield CCS twist.

General appearance:

HEENT:

Pulmonary:

Cardiovascular/hemodynamic:

Abdominal:

Skin and lymphatic:

Musculoskeletal:

Neurologic:

Diagnostic Workup — Initial Labs

— Quantitative serum immunoglobulins: IgG, IgA, IgM (cornerstone test)

— CBC with differential (lymphopenia? cytopenias?)

— Comprehensive metabolic panel (albumin — protein loss?)

— Urinalysis (proteinuria → nephrotic)

— HIV antigen/antibody (always rule out)

— Serum protein electrophoresis (SPEP) with immunofixation — detect myeloma M-spike OR hypogammaglobulinemia pattern

— IgG <600 mg/dL is low; <400 mg/dL clearly significant

— CVID requires IgG >2 SD below mean plus low IgA and/or IgM, age >4, exclusion of secondary causes, and poor vaccine response

— Drug review: rituximab within 6–12 months, chronic steroids, antiepileptics, MMF

— Protein loss: spot urine protein/creatinine; if GI loss suspected, stool alpha-1 antitrypsin clearance

— Malignancy screen: SPEP/UPEP, serum free light chains, peripheral smear, flow cytometry if lymphocytosis (CLL)

— Thymoma: chest CT in adults with new hypogammaglobulinemia → Good syndrome

— Sputum and blood cultures; specifically request Mycoplasma/Ureaplasma PCR for unusual arthritis or pneumonia

— Stool studies including Giardia antigen and Cryptosporidium

— Chest imaging (CXR first; HRCT for bronchiectasis/GLILD)

— Pulmonary function tests (spirometry, DLCO)

— HRCT chest — establish bronchiectasis baseline

— Liver enzymes (nodular regenerative hyperplasia common in CVID)

CCS pearl: On a CCS case with recurrent pneumonia, ordering "quantitative immunoglobulins" + "SPEP" + "HIV" together early scores efficiency points and triages primary vs secondary causes in one move.

First-tier labs (order on any suspected case):

Interpretation thresholds (adult):

Identify the cause of low IgG:

Infection-directed studies (during acute illness):

Baseline organ assessment:

Diagnostic Workup — Advanced/Confirmatory Studies

— Pneumococcal polysaccharide (PPSV23) challenge: measure anti-pneumococcal titers pre- and 4–6 weeks post-vaccination

— Adequate response: protective titers (≥1.3 µg/mL) to ≥70% of serotypes in adults

— Tetanus and diphtheria (protein antigens) titers — response to T-cell–dependent antigens

— Specific antibody deficiency: normal IgG but failed vaccine response — still benefits from replacement in selected patients

— Avoid giving IVIG before testing — wipes out the diagnostic window for 4–6 months

— CD19+ B cells: absent in XLA, normal/low in CVID

— CD4/CD8 T cells: low CD4 suggests combined immunodeficiency

— Memory B cells (CD27+): reduced switched memory B cells (CD27+IgD−) define CVID phenotype and predict complications

— BTK gene → XLA

— CD40L/CD40 → hyper-IgM

— CVID-associated genes: TACI, ICOS, NFKB1, CTLA4, LRBA, PIK3CD (activated PI3K-delta)

— Refer to immunology for next-generation sequencing panels

— HRCT chest for bronchiectasis (tram tracks, signet ring) and GLILD (nodules, ground glass)

— Abdominal imaging for splenomegaly, lymphadenopathy

— Lymph node biopsy if lymphoma suspected (CVID has elevated lymphoma risk)

— GI biopsy for nodular lymphoid hyperplasia, sprue-like changes, CMV

— Lung biopsy for GLILD before immunosuppression

Board pearl: Order pneumococcal titers, then vaccinate with PPSV23, then re-check titers — failed conversion is the functional definition of antibody deficiency and the gatekeeper for IVIG approval by most US payers.

Vaccine response testing (functional antibody assessment):

Lymphocyte subsets (flow cytometry):

Genetic testing:

Imaging deep-dive:

Tissue diagnosis when indicated:

Risk Stratification and First-Line Management Logic

— Step 1: Identify and reverse secondary causes (stop offending drug if possible, treat myeloma/CLL, repair protein loss, remove thymoma)

— Step 2: Quantify infection burden and end-organ damage (bronchiectasis, PFTs)

— Step 3: Assess functional antibody response → decide on replacement

— XLA, hyper-IgM, CVID with infections

— Secondary hypogammaglobulinemia with IgG <400 AND recurrent/serious infections AND poor vaccine response

— Specific antibody deficiency with severe phenotype after failed prophylactic antibiotics

— Post-HSCT with persistent hypogammaglobulinemia and infection

— Asymptomatic selective IgA deficiency (most common PID; do NOT give IVIG — risk anaphylaxis from anti-IgA)

— Isolated low IgG without infections or vaccine failure (observe, repeat)

— Transient hypogammaglobulinemia of infancy (resolves by age 2–4)

— High-risk: bronchiectasis, GLILD, autoimmune cytopenias, granulomas, splenomegaly, lymphoma — refer to immunology

— Moderate: recurrent sinopulmonary infections without structural damage

— Low: mild infections, may trial prophylactic antibiotics first in specific antibody deficiency

— Give inactivated vaccines (influenza, pneumococcal PCV20 or PCV15+PPSV23, COVID) — even with blunted response

— Avoid live vaccines (MMR, varicella, yellow fever, oral polio, intranasal flu, BCG) in significant antibody/combined deficiency

Step 3 management: Before starting IVIG, always check IgA level — patients with absent IgA and anti-IgA antibodies can have anaphylaxis to IgA-containing IVIG. Use IgA-depleted product or subcutaneous Ig.

Decision tree once hypogammaglobulinemia confirmed:

Indications for immunoglobulin replacement (US consensus):

Who does NOT need replacement:

Risk stratification for severity:

Vaccination strategy:

Pharmacotherapy — Immunoglobulin Replacement Regimens

— Dose: 400–600 mg/kg every 3–4 weeks; titrate by trough and clinical response

— Infused over 2–4 hours; premedicate with acetaminophen ± diphenhydramine for reactions

— Steady-state troughs achieved after 3–6 months

— Setting: infusion center or home infusion

— Dose: weekly (~100–150 mg/kg) or biweekly; some products allow facilitated SCIG (hyaluronidase) monthly

— Smaller volumes, steadier IgG levels (no peak/trough swings)

— Self-administered at home — preferred for many adults

— Lower rate of systemic reactions; local site reactions common

— Antibiotic prophylaxis (azithromycin 250 mg 3×/week, or TMP-SMX, or amoxicillin) — adjunct in bronchiectasis or breakthrough infections despite IgG replacement

— Airway clearance, inhaled saline, chest physiotherapy

— Treat H. pylori aggressively (gastric cancer risk in CVID)

— Check IgG trough every 3–6 months, infection log, AE diary

— LFTs, renal function annually (rare IVIG-related AKI, hemolysis, thromboembolism)

— Adjust dose if breakthrough infections persist despite "normal" trough

— IVIG: headache (most common; aseptic meningitis if severe), thromboembolism (especially elderly, hyperviscosity), AKI (sucrose-containing older products), hemolysis (anti-A/anti-B isohemagglutinins), anaphylaxis in IgA-deficient patients

— SCIG: local swelling, erythema, pruritus

Board pearl: Slower infusion rate + hydration reduces IVIG headache, AKI, and thrombosis risk. In patients with thrombotic risk factors (elderly, obese, prior VTE, estrogen use), default to SCIG.

Goal: maintain trough IgG that prevents infections — historically ≥500 mg/dL above baseline, but individualize; many patients need trough ≥700–800, some ≥1000 mg/dL for bronchiectasis control.

IVIG (intravenous immunoglobulin):

SCIG (subcutaneous immunoglobulin):

Adjunctive therapies:

Monitoring during replacement:

Adverse effects to anticipate:

Expanded Pharmacology — Product Selection and Special Situations

— All US IVIG/SCIG products are pooled human plasma, nanofiltered/solvent-detergent treated — extremely low infection transmission risk

— IgA content varies: choose low-IgA products (e.g., certain brands marketed as such) for IgA-deficient patients with anti-IgA antibodies

— Sucrose-free formulations preferred — older sucrose-stabilized products caused osmotic nephrosis

— 10% concentration faster infusion; 5% better tolerated in cardiac/renal patients

— Conversion: weekly SCIG dose ≈ monthly IVIG dose ÷ 4, often ×1.37 dose adjustment factor (varies by product)

— Begin SCIG ~1 week after last IVIG dose

— CMV-IG, VZIG, HBIG, tetanus IG, rabies IG — pathogen-targeted, not for chronic replacement

— Culture-directed antibiotics; lower threshold for prolonged courses

— Increase IgG dose or shorten interval if recurrent

— Add rotating antibiotic prophylaxis (azithromycin pulse)

— Evaluate for new structural disease (HRCT, sinus CT)

— Post-rituximab: typically recovers in 6–12 months; replace only if symptomatic infections

— MMF, anti-epileptics: consider switching if feasible

— CAR-T therapy: prolonged B-cell aplasia → replacement common

— IVIG is expensive (~$8,000–$15,000/month); prior authorization typically requires documentation of low IgG and poor vaccine response

— Home SCIG often more cost-effective and lifestyle-friendly

Step 3 management: When prior auth denies IVIG for a borderline IgG patient, the deciding documentation is usually failed pneumococcal vaccine response plus culture-documented recurrent infections — collect both proactively.

Product considerations:

Switching IVIG ↔ SCIG:

Hyperimmune globulin products (topic-adjacent, sometimes tested):

Managing breakthrough infections despite replacement:

Drug-induced hypogammaglobulinemia management:

Cost and access (Step 3 systems thinking):

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline prevalence of secondary hypogammaglobulinemia (CLL, myeloma, chronic steroids)

— Always rule out occult plasma cell dyscrasia with SPEP, free light chains, marrow if indicated — before labeling as CVID

— Vaccine responses are physiologically blunted (immunosenescence) — interpret titer testing cautiously

— Higher risk of IVIG-related thromboembolism, AKI, volume overload, and hemolysis

— Prefer SCIG or slower IVIG infusion rates; pre-hydrate; consider aspirin if VTE risk

— Avoid sucrose-stabilized IVIG (largely off-market in US but worth knowing)

— Use lower infusion rate and lower concentration (5%)

— Monitor BUN/creatinine before and after infusions initially

— Maintain euvolemia; avoid volume contraction

— SCIG often safer in CKD because avoids large bolus volumes

— No major dose adjustment, but transaminitis must be evaluated — CVID itself causes nodular regenerative hyperplasia and portal hypertension

— Screen for hepatitis B/C before therapy; though product-transmitted infection is exceedingly rare, baseline serologies matter

— Heart failure patients risk volume overload from 10% IVIG infusions

— Slow infusions, low concentration, or convert to SCIG

— Watch for arrhythmia during infusion in elderly

— Estrogens, tamoxifen, EPO — additive thrombosis risk with IVIG

— Live vaccines after IVIG: defer 8–11 months (passive antibody blunts response)

Key distinction: A new IgG monoclonal spike in an elderly patient with hypogammaglobulinemia is multiple myeloma until proven otherwise — not CVID. The polyclonal background is suppressed by the malignant clone.

Elderly patients:

Renal impairment:

Hepatic impairment:

Cardiac comorbidity:

Polypharmacy considerations:

Special Populations — Pregnancy and Pediatrics

— IVIG and SCIG are safe in pregnancy (no fetal harm; routinely used for ITP, hemolytic disease, etc.)

— Maternal IgG demand increases — monitor trough every trimester; dose typically increases ~20–50% by third trimester due to volume expansion and placental transfer

— Active IgG transport across placenta begins ~16 weeks, peaks third trimester — replacement protects neonate

— Continue without interruption peripartum

— Live vaccines remain contraindicated in mother and in infant for 8–11 months postpartum (passive Ig interferes with vaccine response)

— Maternal IgG wanes by 4–6 months → physiologic nadir; pathologic if infections begin then

— Transient hypogammaglobulinemia of infancy: low IgG with normal vaccine responses; resolves by 2–4 years; usually no replacement needed unless severe infections

— XLA: male infant, recurrent encapsulated infections after 6 months, absent tonsils, absent B cells — start IVIG/SCIG promptly; avoid live vaccines (especially oral polio historically, rotavirus today)

— Hyper-IgM: add PCP prophylaxis (TMP-SMX); high risk for opportunistic infections including Cryptosporidium → boil/filter water

— Growth and development tracking; school attendance counseling

— Plan transfer from pediatric to adult immunology around age 18–21

— Reinforce self-administration of SCIG, adherence, recognition of infections

— Discuss reproductive planning, genetic counseling for X-linked or autosomal recessive PIDs

CCS pearl: A pregnant CVID patient on stable IVIG who develops breakthrough sinusitis in the second trimester — increase the IVIG dose or shorten the interval, don't just add antibiotics. Trough goals rise with pregnancy physiology.

Pregnancy:

Pediatric considerations:

Adolescent transition:

Complications and Adverse Outcomes

— Bronchiectasis — the most common and morbid structural complication; once established, irreversible

— Recurrent pneumonia, empyema, lung abscess

— Chronic sinusitis with mucosal damage, osteitis

— Mycoplasma/Ureaplasma septic arthritis — destructive, hard to culture, requires extended doxycycline/macrolide therapy

— Chronic enteroviral meningoencephalitis (insidious, progressive) — devastating, especially XLA

— Chronic Giardia, Cryptosporidium → malabsorption, weight loss

— GLILD — restrictive lung disease, mortality driver; treat with rituximab + azathioprine or MMF

— Autoimmune cytopenias (ITP, AIHA, Evans) — often the presenting feature

— Granulomatous disease — sarcoid-like, multi-organ

— Nodular regenerative hyperplasia of liver → portal hypertension

— Enteropathy: sprue-like, nodular lymphoid hyperplasia, IBD-like

— Malignancy: NHL (especially MALT), gastric adenocarcinoma — screen for H. pylori and treat

— Aseptic meningitis (slow rate, hydrate)

— Thromboembolism — MI, stroke, DVT/PE

— Acute kidney injury

— Hemolysis from anti-A/B isohemagglutinins (esp. blood groups A, AB)

— Anaphylaxis (IgA-deficient patients)

— TRALI (rare)

— With replacement, life expectancy approaches normal in uncomplicated CVID; reduced if GLILD, lymphoma, or enteropathy develops

— Quality of life improved with SCIG self-administration

Board pearl: Sudden hemoglobin drop 5–10 days after IVIG = isohemagglutinin-mediated hemolysis, especially in patients with blood type A or AB receiving high-dose IVIG. Check DAT, haptoglobin, LDH.

Infection-related:

Non-infectious complications of CVID specifically:

Therapy-related complications (IVIG):

Long-term outcomes:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Clinical immunology/allergy: any newly diagnosed primary immunodeficiency, before starting Ig replacement

— Hematology/oncology: M-spike, lymphadenopathy, splenomegaly, cytopenias — rule out CLL, myeloma, lymphoma

— Pulmonology: bronchiectasis management, GLILD evaluation, PFT trends

— Gastroenterology: chronic diarrhea, suspected enteropathy, biopsy

— Infectious disease: opportunistic, atypical, or resistant infections

— Genetics: family planning, pediatric PID, syndromic features

— Pneumonia with hypoxia, sepsis criteria, or failed outpatient antibiotics

— Severe IVIG reaction (anaphylaxis, aseptic meningitis with intractable symptoms, AKI)

— Suspected meningoencephalitis (LP, MRI, ID consult)

— Newly recognized severe cytopenia

— Septic shock — fluids, broad-spectrum antibiotics covering encapsulated organisms (ceftriaxone + macrolide), source control

— Respiratory failure from pneumonia or GLILD exacerbation

— Severe IVIG anaphylaxis with hemodynamic instability

— Cultures (blood, sputum, urine, stool, CSF if indicated) before antibiotics when feasible

— Empiric coverage for encapsulated bacteria

— Check current IgG trough — under-replacement?

— Update HRCT to assess structural damage

— Coordinate with immunology for dose adjustment post-discharge

— Confirm next IVIG/SCIG infusion is scheduled before discharge

— Update immunology and PCP on inpatient course

— Document vaccine plan (no live vaccines)

Step 3 management: A CVID patient admitted with pneumococcal pneumonia despite IVIG → after stabilization, recheck IgG trough and consider dose escalation or interval shortening, plus add macrolide prophylaxis if bronchiectasis present.

Specialist referrals (must-do for Step 3):

Inpatient admission criteria:

ICU triage:

Acute breakthrough infection workflow (CCS-style):

Transition of care:

Key Differentials — Same-Category (Immune) Causes

— Most common PID overall; most asymptomatic

— Recurrent sinopulmonary or GI infections in symptomatic minority

— No IVIG (risk of anti-IgA anaphylaxis); manage infections symptomatically

— Test for celiac disease; use IgG-based celiac serologies given low IgA

— Low IgG + low IgA and/or IgM, poor vaccine response, age >4, no secondary cause

— Autoimmunity, granulomas, lymphoma risk

— Male infants, absent B cells, absent tonsils/nodes, BTK mutation

— Normal/high IgM, low IgG/IgA, susceptibility to PCP, Cryptosporidium (CD40L-X-linked); add PCP prophylaxis

— Normal total IgG, but failed pneumococcal polysaccharide response

— Try prophylactic antibiotics first; IVIG if severe

— SCID (neonatal, lymphopenia, failure to thrive, opportunistic infections) — treat with HSCT

— DiGeorge: T-cell defect with hypocalcemia, conotruncal cardiac defects

— Wiskott-Aldrich: eczema, thrombocytopenia (small platelets), immunodeficiency — X-linked male

— Ataxia-telangiectasia: cerebellar ataxia, oculocutaneous telangiectasias, low IgA/IgE

— Thymoma + hypogammaglobulinemia in adult — CT chest mandatory in new adult hypogammaglobulinemia

Key distinction: Selective IgA deficiency vs CVID — both can present with sinopulmonary infections, but IgA deficiency has normal IgG; only CVID warrants Ig replacement. Mislabeling IgA deficiency and giving IVIG = anaphylaxis risk.

Selective IgA deficiency:

CVID:

XLA (Bruton):

Hyper-IgM syndromes (CD40L, AID deficiencies):

Specific antibody deficiency:

Combined immunodeficiencies:

Good syndrome:

Key Differentials — Other-Category (Secondary) Causes

— Chronic lymphocytic leukemia (CLL): lymphocytosis, smudge cells, hypogammaglobulinemia from disordered B-cell function and treatment; IVIG indicated for recurrent infections with IgG <500 and documented infections

— Multiple myeloma: monoclonal IgG/IgA spike with suppression of other immunoglobulin classes ("immunoparesis"); CRAB features

— Non-Hodgkin lymphoma: after rituximab-containing chemo

— Waldenström macroglobulinemia: IgM spike, hyperviscosity, hypogammaglobulinemia of other classes

— Anti-CD20 monoclonals (rituximab, obinutuzumab, ocrelizumab) — most common iatrogenic cause; persistent in some patients

— Corticosteroids (chronic, high-dose)

— Anti-epileptics: phenytoin, carbamazepine, valproate, lamotrigine

— Mycophenolate, methotrexate, cyclophosphamide

— CAR-T therapy, bispecific T-cell engagers

— Nephrotic syndrome — proteinuria, hypoalbuminemia, edema; check urine protein

— Protein-losing enteropathy — IBD, intestinal lymphangiectasia, Ménétrier; check stool α1-antitrypsin clearance

— Severe burns, chylothorax

— Typically causes hypergammaglobulinemia (polyclonal), but late disease and post-treatment can be hypogammaglobulinemic; always check HIV

— Solid organ or HSCT recipients on immunosuppression; IVIG replacement common

Board pearl: Adult with new hypogammaglobulinemia → the order of workup is drug history → SPEP/free light chains → chest CT (thymoma) → HIV → urine and stool protein loss → then primary immunodeficiency. Don't skip the secondary screen.

Hematologic malignancies (most tested):

Drug-induced:

Protein loss:

HIV/AIDS:

Post-transplant:

Severe malnutrition, sepsis with capillary leak.

Secondary Prevention, Discharge Plan, and Long-Term Management

— Lifelong Ig replacement with individualized trough goals

— Antibiotic prophylaxis when bronchiectasis or recurrent breakthrough: azithromycin 250 mg M/W/F, or daily amoxicillin, or TMP-SMX

— PCP prophylaxis in hyper-IgM and combined deficiencies (TMP-SMX)

— Hand hygiene, mask in high-risk settings, avoid sick contacts

— Food/water safety to prevent Giardia, Cryptosporidium (filtered water in hyper-IgM)

— Annual inactivated influenza, PCV20 (or PCV15 + PPSV23), COVID boosters per current schedule, Tdap booster q10y, RSV per age guidance, HPV if age-appropriate

— Avoid live vaccines (MMR, varicella, zoster live, yellow fever, BCG, oral typhoid, oral polio, intranasal flu, oral rotavirus, smallpox)

— Use recombinant zoster (Shingrix) — non-live, safe

— Vaccinate household contacts to provide ring protection (inactivated flu, etc.); avoid live vaccines in close contacts of severely immunodeficient patients

— Annual H. pylori testing/eradication strategy; consider periodic upper endoscopy given gastric cancer risk

— Vigilance for lymphoma — new adenopathy, B symptoms

— Skin cancer screening

— Airway clearance (vest, flutter), inhaled hypertonic saline, bronchodilators

— Annual PFTs, periodic HRCT (every 2–4 years or sooner if change)

— Pulmonary rehab in bronchiectasis

— Carry a card listing diagnosis, no-live-vaccine status, IgA-deficient (if applicable)

— Early-symptom action plan with antibiotic course on hand

Step 3 management: When CVID patient is discharged after pneumonia, the longitudinal plan must include: (1) IgG trough recheck, (2) HRCT update, (3) pneumococcal titers/revaccination, (4) immunology follow-up in 2–4 weeks, (5) consideration of macrolide prophylaxis.

Infection prevention bundle:

Vaccination plan:

Cancer surveillance (CVID):

Pulmonary maintenance:

Patient education:

Follow-Up, Monitoring, and Counseling

— IgG trough: every 3 months until stable, then every 6 months

— Infection diary: number, type, severity, antibiotic days

— CBC, CMP, LFTs: every 6–12 months (hemolysis, NRH, AKI surveillance)

— Annual urinalysis (proteinuria — IVIG-related uncommon; comorbidity check)

— PFTs annually; HRCT every 2–4 years or when symptoms change

— Annual H. pylori screen/eradication strategy

— Lymph node, spleen size exam each visit

— Breakthrough infection → recheck trough, increase dose 25%, reassess in 3 months

— Persistent breakthroughs → shorten interval, add antibiotic prophylaxis, evaluate for new structural disease

— Stable, infection-free for 1+ year → consider trough at goal, maintain

— Adherence: missed infusions cause infection clustering — emphasize importance

— Travel: pre-trip immunology consult; avoid live vaccines; carry diagnosis card; food/water precautions

— Reproductive counseling: genetic counseling for inherited PIDs; safety of Ig in pregnancy

— Mental health: chronic disease, infusion burden, lymphoma anxiety — screen for depression

— Fertility and family planning: SCIG self-administration education for childbearing-age patients

— Pulmonary rehab if bronchiectasis

— Smoking cessation (critical — amplifies lung damage)

— Exercise, balanced nutrition, vitamin D

— Immunology as quarterback

— PCP, pulmonologist, GI as needed

— Pharmacy/home infusion partnership for SCIG

CCS pearl: Order recurring "immunoglobulin levels q3 months" plus annual influenza vaccine and pneumococcal series per schedule on the orders sheet — these are easy points on a Step 3 CCS case.

Routine monitoring cadence:

Adjusting replacement therapy:

Counseling points:

Rehabilitation and lifestyle:

Care team coordination:

Ethical, Legal, and Patient Safety Considerations

— Discuss lifelong therapy, cost, infusion reactions, thromboembolism, AKI, aseptic meningitis, anaphylaxis in IgA-deficient patients

— Document alternative options (antibiotic prophylaxis alone in mild specific antibody deficiency)

— Plasma-derived product — discuss theoretical (extremely low) infection transmission risk; this is a recurring informed-consent stem

— Patient and household contacts must be educated to avoid live vaccines that could shed (oral polio—now rare in US, rotavirus in infants—precautions around diaper handling, smallpox vaccinees)

— School/daycare communication for children with PID

— X-linked conditions (XLA, hyper-IgM CD40L, Wiskott-Aldrich): female carriers have 50% risk of affected sons — duty to discuss with at-risk family

— Pediatric assent and parental consent for genetic testing

— Hospital discharge: ensure next outpatient Ig infusion is scheduled; gaps drive readmissions

— Care transitions from pediatric to adult immunology — structured handoff prevents loss to follow-up

— Cross-coverage: any inpatient team must know no live vaccines and antibiotic threshold is lower

— Prior authorization requires documented diagnosis, low IgG, failed vaccine response, and clinical infection burden — anticipate and document

— Home infusion vs infusion center — patient-centered decision, equity considerations for rural patients

— Newborn screening for SCID (TREC assay) is universal in the US — failed screen requires urgent immunology referral; this is a reportable lab result in most states

— Tuberculosis, certain STIs — standard mandatory reporting still applies; PID does not change duty

— Advanced GLILD or lymphoma in CVID — discuss palliative options, code status

Board pearl: Universal newborn SCID screening (TREC) has transformed outcomes — early HSCT before 3.5 months yields >95% survival. A positive screen on a newborn is a Step 3 immunology emergency: immediate immunology referral, isolation precautions, no live vaccines including rotavirus, irradiated CMV-negative blood products.

Informed consent for Ig replacement:

Live vaccine safety:

Genetic counseling and disclosure:

Transition-of-care safety (Step 3 favorite):

Insurance and access:

Mandatory reporting and public health:

End-of-life and goals-of-care:

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: Hypergammaglobulinemia of HIV/cirrhosis ≠ hypogammaglobulinemia — late-stage HIV can have functional antibody deficiency despite normal totals; functional vaccine testing matters more than absolute number.

CVID + ITP/AIHA → autoimmune cytopenias are the most common autoimmune presentation

CVID + bronchiectasis → check IgG trough, consider dose increase + macrolide prophylaxis

CVID + chronic diarrhea → think Giardia, nodular lymphoid hyperplasia, CMV enteritis, sprue-like

CVID + splenomegaly + lymphadenopathy → don't miss lymphoma (NHL risk elevated)

CVID + gastric symptoms → screen and treat H. pylori; high gastric cancer risk

CVID + restrictive PFT + ground glass on HRCT → GLILD, treat with rituximab-based regimen

Thymoma + adult-onset hypogammaglobulinemia → Good syndrome; chest CT in every new adult hypogammaglobulinemia case

Male infant + absent tonsils + recurrent encapsulated infections after 6 months → XLA (BTK)

Normal/high IgM, low IgG/IgA, PCP pneumonia in boy → Hyper-IgM (CD40L); add PCP prophylaxis

Selective IgA deficiency + anaphylaxis to blood product → anti-IgA antibodies; use washed RBCs / IgA-deficient donors

Post-rituximab + recurrent infections → check IgG; replace if <400 with infections

New M-spike + low background Igs in older adult → myeloma, not CVID

CLL + recurrent encapsulated infections + IgG <500 → IVIG indicated

IgG infusion + headache 24h later → IVIG-related aseptic meningitis; slow rate, hydrate

IVIG + day 5–10 anemia + low haptoglobin → isohemagglutinin hemolysis, esp. blood type A/AB

CVID patient travel → no yellow fever vaccine; food/water care; carry antibiotics

Mycoplasma/Ureaplasma septic arthritis → think antibody deficiency

Bronchiectasis in non-smoker non-CF adult → quantitative immunoglobulins, sweat chloride, ciliary studies

Cryptosporidium chronic diarrhea in boy with PCP → hyper-IgM with CD40L; nitazoxanide, boiled water

Board Question Stem Patterns

— 30-year-old with 3 pneumonias in 2 years, sinusitis, otitis; CXR shows bronchiectasis

— Best next step: quantitative immunoglobulins, then SPEP, HIV, pneumococcal vaccine response

— Final diagnosis: CVID; treat with IVIG or SCIG

— Patient with known selective IgA deficiency receives blood transfusion or IVIG → anaphylaxis

— Mechanism: anti-IgA antibodies; use washed RBCs or IgA-depleted Ig product

— Recurrent otitis, pneumonia, absent tonsils, low B cells

— Diagnosis: XLA (BTK mutation); start Ig replacement; avoid live vaccines

— Lymphoma survivor with recurrent pneumonias and IgG 300

— Management: IVIG replacement, document infections and vaccine failure for prior auth

— Anemia, bone pain, low IgG, monoclonal IgG kappa spike → multiple myeloma, not CVID

— Adult with mediastinal mass + recurrent infections + low IgG → Good syndrome; thymectomy doesn't resolve hypogammaglobulinemia

— Young boy with PCP pneumonia, normal IgM, low IgG/IgA → CD40L deficiency; PCP prophylaxis, boiled water for Crypto

— Type AB patient gets high-dose IVIG, drops Hb 5 days later → isohemagglutinin hemolysis

— Chronic destructive arthritis with negative cultures in hypogammaglobulinemic patient → Ureaplasma/Mycoplasma; doxycycline/macrolide

— Patient with normal total IgG but recurrent infections → specific antibody deficiency; check pre/post pneumococcal titers

Step 3 management: When the stem asks "best next step," favor quantitative immunoglobulins + SPEP + HIV as the screening trio; when it asks "definitive treatment," favor IVIG/SCIG replacement plus addressing the underlying cause (stop drug, treat malignancy, remove thymoma).

Pattern 1 — Adult with recurrent sinopulmonary infections:

Pattern 2 — IgA deficiency anaphylaxis:

Pattern 3 — Male infant with infections after 6 months:

Pattern 4 — Post-rituximab patient:

Pattern 5 — Older adult with new hypogammaglobulinemia:

Pattern 6 — Thymoma:

Pattern 7 — Hyper-IgM:

Pattern 8 — IVIG hemolysis:

Pattern 9 — Mycoplasma arthritis:

Pattern 10 — Vaccine response testing:

One-Line Recap

Hypogammaglobulinemia management hinges on confirming reduced IgG with poor vaccine response, ruling out secondary causes (drugs, malignancy, protein loss, HIV, thymoma) before labeling primary immunodeficiency, and instituting lifelong IVIG or SCIG replacement titrated to clinical infection control alongside vaccination, antibiotic prophylaxis when indicated, and vigilant surveillance for bronchiectasis, autoimmunity, and lymphoma.

Board pearl: The single highest-yield Step 3 reflex for this topic is: recurrent encapsulated-organism infections + low IgG → check SPEP, HIV, drug list, and chest CT first; if all negative and vaccine response is poor, diagnose CVID and start Ig replacement — but always document IgA level before the first infusion.

Diagnostic core: Quantitative IgG/IgA/IgM + SPEP/free light chains + HIV + drug review + chest CT (thymoma) + pneumococcal/tetanus vaccine response titers; lymphocyte subsets and memory B cells refine PID phenotype.

Therapeutic core: IVIG 400–600 mg/kg q3–4 weeks or weekly SCIG, individualized trough (often ≥700–800 mg/dL, higher if bronchiectasis); always screen for IgA deficiency with anti-IgA antibodies before first dose to prevent anaphylaxis.

Longitudinal core: Inactivated vaccines yes, live vaccines no; annual flu, pneumococcal series, COVID boosters, Shingrix; H. pylori eradication; PFTs annually; lymphoma vigilance; pulmonary rehab and airway clearance for bronchiectasis.

Safety core: Slow IVIG rate + hydration to prevent headache, AKI, and thrombosis; recognize delayed isohemagglutinin hemolysis in type A/AB patients; transition-of-care planning ensures no gap between hospital discharge and next infusion.